3Shrier LA, Dean D, Klein E, et al. Limitations of screening tests for the detection of Chlamydia trachomatis in asymptomatic adolescent and young adult woman[ J ]. Am J Obstet Gynecol, 2004,190(3 ) :654-662.
4Gruson D, Pereyre S, Renaudin H, et ol. In vitro development of resistance to six and four fluoroquinolones in mycoplasma pneumoniae and mycoplasma hominis, respectively [J] Antimicrobial Agents and Chemotherapy,2005, (49) : 1190-1193.
6Zhang W, Wu Y, Yin W, et al. Study of isolation of fluoroquinolone resisrant Ureaplasma urelyticum and identification of mutant sites[J]. Chin Med J(Engl), 2002,115(10) : 1573.
7Pereyre S,Renandin H, Bebear C, et al. In vitro activities of the newer quinolones garenoxacin, gatitloxacin, and gemifloxacin against human mycoplasmas[ J ]. Antimicrobial Agents Chemother, 2004, ( 48 ) : 3165-3168.
9Gulbinovic J, Myrback K E, Bytautiene J, et al. Marked differences in antibiotic use and resistance between university hospitals in Vilnius, Lithuania, and Huddinge, Sweden[ J ].Microb Drug Resist, 2001, 7:383-389.
10WHO Collaborating Centre for Drug Statistics Menthology[M]. WHO ACT Index with DDDs, 2005.
